Abilify (aripiprazole), 15 mg tablets, packaged in 30 count bottles, RX only, Otsuka America Pharmaceutical, Inc., NDC 59148-009-13

FDA recall notice · announced May 1, 2024 · Second Tokushima Factory, Otsuka Pharmaceutical Co

Class III FDA/FSIS Class III: use is not likely to cause adverse health consequences.

The product

Abilify (aripiprazole), 15 mg tablets, packaged in 30 count bottles, RX only, Otsuka America Pharmaceutical, Inc., NDC 59148-009-13

Reason for recall

Cross Contamination with Other Products

Notes

Distribution: USA nationwide.
Lot/code information: Lot # AMS00223A, Exp 07/31/2025
Quantity: N/A
Status: Ongoing
Products in this recall event:
- Abilify (aripiprazole), 5 mg tablets, packaged in 30 count bottles, RX only, Otsuka America Pharmaceutical, Inc., NDC 59148-007-13 (D-0466-2024)
- Abilify (aripiprazole), 10 mg tablets, packaged in a) 30 count bottles (NDC 59148-008-13) and b) 7 count blister packs (NDC 59148-008-95), RX only, Otsuka America Pharmaceutical, Inc. (D-0467-2024)
- Abilify (aripiprazole), 30 mg tablets, packaged in 30 count bottles, RX only, Otsuka America Pharmaceutical, Inc., NDC 59148-011-13 (D-0469-2024)
- Abilify (aripiprazole), 15 mg tablets, packaged in 30 count bottles, RX only, Otsuka America Pharmaceutical, Inc., NDC 59148-009-13 (D-0468-2024)

Source: U.S. Food and Drug Administration public recall data. This page reports official records and is not legal, medical, or repair advice.